SmartTRAK identifies the top trends impacting the Compression Therapy Market in 2023 and beyond, including reimbursement, diagnostic aids, 3M’s spin-off and growth in compression wraps.

Over the next several years, reimbursement changes in the US could impact the US Compression Therapy Market, In 2020, SmartTRAK noted that industry participants should expect increased activity from US advocacy groups seeking to raise awareness of reimbursement restrictions on compression therapy products. 

Among the top trends impacting the Compression Market in 2023 covered in detail in this article are:

• Trend #1: Expanding Coverage of Lymphedema Compression Therapy
  •  In December 2022, advocacy efforts were rewarded when legislators added coverage of lymphedema compression treatment items to the $1.7 trillion US Consolidated Appropriations Act, 2023 (H.R. 2617). Among many other provisions, the Bill provides Medicare coverage of ...
    
    
• Trend #2: Innovation in Diagnostic Aids
  • The lack of objective measurement of lymphatic function hinders the effective diagnosis and treatment of lymphedema. Lymphedema is typically diagnosed based on a patient’s underlying risk factors and physical symptoms. In some cases, imaging technology such as ...
    
    
• Trend #3: 3M’s Health Care Spin-off Shifting Market Dynamics
  • SmartTRAK noted in a recent article that 3M’s spin-off of its Health Care business could lead to a more focused and stronger leader in advanced wound care. SmartTRAK does not categorize compression therapy as advanced wound care, however, compression is ...
    
    
• Trend #4: Growth in Compression Wraps
  • SmartTRAK continues to track the growth of compression wraps via publicly available data sources. Compression wraps are growing strong in the UK, driven by the belief that the products improve patient compliance, reduce the need for professional intervention and are more cost-effective. The same drivers support growth in the US; however, the US Medicare system only provides reimbursement of compression wraps for qualifying wounds ...
    

To download and read the complete "Compression Therapy Trends to Watch in 2023 and Beyond" article by Terry Hayslett, SmartTRAK's Senior Analyst, Advanced Wound Care. just click the button below.

• New Product Launches Coming Back
• Transitioning to the European Medical Device Regulations
• Continued Macroeconomic Headwinds in Specific Countries
• The Reimbursement-Related Threat of Silver Dressings in Germany

Breast Matrices rebound and grow modestly as AbbVie’s competitors take over market share. Biosynthetic and hybrid xenograft hernia matrices continue to drive growth in Hernia Matrices.

The US Surgical Matrices Market resumed its pre-pandemic trends, gaining +3.2% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) remained in first and second positions, respectively, in the Q422 Surgical Matrices market. AbbVie held on to its leadership despite  a -4.4% YoY decline, while BD gained +6.1% YoY.

Among the many topics covered in detail in our comprehensive Q422 US Surgical Matrices Market Recap* are:

Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK

With the US launch of the Evoke System, Saluda Medical is changing the game in spinal cord stimulation (SCS). At the North American Neuromodulation Society (NANS) Annual meeting in Las Vegas in January, researchers presented impressive 36-month data from the Company’s Evoke Study and the Company was showcasing its Evoke System for the first time on the NANS exhibit hall floor. As the first commercially available closed-loop SCS system using evoked compound action potentials (ECAPs), Evoke is unlike anything on the market. The technology automatically adjusts stimulation to maintain precise and consistent neural activation to the spinal cord for the treatment of intractable low back and leg pain. The Company received FDA PMA for Evoke in February 2022 and announced a limited US commercial release in December 2022, calling it the first and only ‘SmartSCS” in the US.

Saluda Medical President and CEO Jim Schuermann discusses bringing Evoke System to market, the Company’s US launch and commercialization plans, the newest generation of Evoke, his vision for the future and Evoke’s potential impact on the market in an interview with SmartTRAK. Click the button below to download and read a complete transcript of the interview.

SmartTRAK reviews recent trends in hernia matrices and their potential impact on the US Hernia Matrices Market, which is projected to reach $1.06B in 2023 according to SmartTRAK.

Incisional hernia procedures reached a peak in the mid-2000s, with a gradual decline as surgeons performed fewer abdominal procedures and researchers investigated new techniques for closure. While improved stitching for closure has had mixed results, surgeons are trying other new approaches to reduce incisional hernias such as MSI’s DuraMesh* and Deep Blue Medical’s T-line mesh* which are being used prophylactically.

In this Market Outlook article, we cover in detail:

• Synthetic Matrices Poised for Slow Down
• Alternatives to Synthetic Matrices Gaining Favor
  • Xenograft Matrices
  • Resorbable Meshes
  • Reinforced Xenograft Matrices
• Expert Analysis and Conclusions

Market Dynamics, Industry Moves and Technology Advancements 

In 2022, the Orthobiologics Market encountered both ups and downs. Though companies are still reporting year-end results, SmartTRAK feels the Orthobiologics Market finished on a high note. The 2022 challenges, such as staffing shortages at healthcare facilities, supply chain constraints and inflation, may cause headwind in 2023, stifling some growth.

Nevertheless, SmartTRAK anticipates the potential downsides will be offset by elective procedures returning to pre-COVID levels, along with progressive, transitional initiatives by select market players that have the potential to reshape certain orthobiologics segment landscapes.

Among the many topics covered in this Market Outlook article are:

• Reshaping the Competitive Landscape
• Shifts in the US Bone Replacement Market
• Advancements in Osteobiologics
• Shifts in the US Sports Medicine Market

SmartTRAK interviews Advanced Oxygen Therapy Inc CEO and President Dr. Mike Griffiths to discuss how durable healing can improve health equality

Oxygen-based therapies have been used on chronic wounds for many years. In a recent article on the 2023 Oxygen and Energy Market, SmartTRAK expressed the view that the Topical Oxygen Therapy Market will grow at a significant rate and that Advanced Oxygen Therapy Inc* is likely to be the biggest driver of that growth. The Company has established a solid evidence base for its TWO2* system, a Topical Wound Oxygen therapy system which applies cyclical pressurized directly to a patient’s wound at home or in a healthcare facility. SmartTRAK talked with the company Medical Director, President and CEO, Dr. Mike Griffiths, about the journey that the company has been on so far, how durable healing and patient-led home care can reduce health inequalities and why the company has recently entered the Negative Pressure Wound Therapy (NPWT) Market.

To find out more about Advanced Oxygen Therapy Inc, click on the following video to listen to the recorded interview (27:56 min). A complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

With many of the “hard yards” already run, SmartTRAK believes that 2023 could be a promising year for the Oxygen and Energy segments of the Advanced Wound Care Market.

SmartTRAK estimates the 2021 WW Oxygen and Energy Market at just over $50.0MM. While this is not an insignificant amount, it trails far behind other Advanced Wound Care markets such as Negative Pressure Wound Therapy (NPWT) and Biologics. Last year, however, showed signs that clinicians are starting to realize the potential of these technologies. Here SmartTRAK looks at how some of the existing players in the markets for oxygen and energy therapies may show increased success in 2023 and why some of the leading wound care companies may soon be taking their first steps into these markets.

Among the many topics covered in this article are: